Literature DB >> 487927

Association of cimetidine and bone-marrow suppression in man.

F Druart, C Frocrain, P Metois, J Martin, C Matuchansky.   

Abstract

A 29-year old woman who was on steroids for Behcet's disease received intravenous cimetidine for severe gastrointestinal bleeding. A bone-marrow examination performed a few days prior to cimetidine treatment showed a normally active marrow. On the fifth day of cimetidine therapy, agranulocytosis (800/ml) and a very low platelet count (40,000/ml) were observed; bone-marrow failure was documented both by biopsy and aspiration. No other drug known to be myelotoxic was given. This severe hematologic side effect of cimetidine resolved within 10 days after discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 487927     DOI: 10.1007/bf01314472

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Effects of metiamide on gastric acid hypersecretion, steatorrhea, and bone-marrow function in a patient with systemic mastocytosis.

Authors:  E J Feldman; J I Isenberg
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

2.  Transient neutropenia in a patient receiving cimetidine.

Authors:  M H Ufberg; C M Brooks; P R Bosanac; J E Kintzel
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

3.  Cimetidine and bone-marrow toxicity.

Authors:  J W Byron
Journal:  Lancet       Date:  1977-09-10       Impact factor: 79.321

Review 4.  Drug therapy: Cimetidine.

Authors:  W Finkelstein; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

Review 5.  Oral ulceration and Behçet's syndrome.

Authors:  T Lehner
Journal:  Gut       Date:  1977-06       Impact factor: 23.059

6.  Cimetidine therapy in a patient with metiamide-induced agranulocytosis.

Authors:  D Fleischer; I M Samloff
Journal:  N Engl J Med       Date:  1977-02-10       Impact factor: 91.245

7.  Agranulocytosis four months after cimetidine therapy.

Authors:  E R Craven; J M Whittington
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

8.  [Transient marrow aplasia during cimetidine treatment].

Authors:  E Gouffier; D Schnurmann; H Durepaire; J B Vernant
Journal:  Nouv Presse Med       Date:  1978-09-16

9.  Cimetidine for gastric and duodenal ulcer?

Authors:  M J Langman
Journal:  Am J Med       Date:  1978-12       Impact factor: 4.965

10.  Letter: Reversal of metiamide-induced agranulocytosis during treatment with cimetidine.

Authors:  W L Burland; P C Sharpe; D G Colin-Jones; P R Turnbull; P Bowskill
Journal:  Lancet       Date:  1975-11-29       Impact factor: 79.321

View more
  7 in total

Review 1.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Cimetidine-induced bone marrow suppression.

Authors:  E A Pariente; O Nouel
Journal:  Dig Dis Sci       Date:  1980-05       Impact factor: 3.199

3.  Leucopenia and thrombocytopenia with cimetidine.

Authors:  K L Chandrasekhara; S K Iyer; R J Macchia
Journal:  J Natl Med Assoc       Date:  1981-02       Impact factor: 1.798

4.  Cimetidine and hematologic suppression: things are not always as they appear.

Authors:  J E Richter; D C Gerhardt; D N Pasquale; D O Castell
Journal:  Dig Dis Sci       Date:  1980-12       Impact factor: 3.199

5.  Leukopenia with cimetidine.

Authors:  S K Iyer; K L Chandrasekhara
Journal:  J Natl Med Assoc       Date:  1980-08       Impact factor: 1.798

6.  Histopathology of the bone marrow in toxic myelopathy. A study of drug induced lesions in 57 patients.

Authors:  R Krech; J Thiele
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

7.  Assessment of myelotoxicity caused by environmental chemicals.

Authors:  G A Boorman; M I Luster; J H Dean; M L Campbell
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.